Antigens reversibly conjugated to a polymeric glyco-adjuvant induce protective humoral and cellular immunity
Source abstract
Abstract
Fully effective vaccines for complex infections must elicit a diverse repertoire of antibodies (humoral immunity) and CD8+ T-cell responses (cellular immunity). Here, we present a synthetic glyco-adjuvant named p(Man-TLR7), which, when conjugated to antigens, elicits robust humoral and cellular immunity. p(Man-TLR7) is a random copolymer composed of monomers that either target dendritic cells (DCs) via mannose-binding receptors or activate DCs via Toll-like receptor 7 (TLR7). Protein antigens are conjugated to p(Man-TLR7) via a self-immolative linkage that releases chemically unmodified antigen after endocytosis, thus amplifying antigen presentation to T cells. Studies with ovalbumin (OVA)-p(Man-TLR7) conjugates demonstrate that OVA-p(Man-TLR7) generates greater humoral and cellular immunity than OVA conjugated to polymers lacking either mannose targeting or TLR7 ligand. We show significant enhancement of Plasmodium falciparum-derived circumsporozoite protein (CSP)-specific T-cell responses, expansion in the breadth of the αCSP IgG response and increased inhibition of sporozoite invasion into hepatocytes with CSP-p(Man-TLR7) when compared with CSP formulated with MPLA/QS-21-loaded liposomes-the adjuvant used in the most clinically advanced malaria vaccine. We conclude that our antigen-p(Man-TLR7) platform offers a strategy to enhance the immunogenicity of protein subunit vaccines.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Immune Response and Inflammation · Immune Cell Function and Interaction
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (52)
Show source-provided references
1. Moyle, P. M. & Toth, I. Modern subunit vaccines: development, components, and research opportunities. ChemMedChem. 8, 360–376 (2013).10.1002/cmdc.201200487 ↗
2. Seder, R. et al. Gaps in knowledge and prospects for research of adjuvanted vaccines. Vaccine 33, B40–B43 (2015).10.1016/j.vaccine.2015.03.057 ↗
3. Moon, J. J. et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat. Mater. 10, 243–251 (2011).10.1038/nmat2960 ↗
4. Lambrecht, B. N., Kool, M., Willart, M. A. & Hammad, H. Mechanism of action of clinically approved adjuvants. Curr. Opin. Immunol. 21, 23–29 (2009).10.1016/j.coi.2009.01.004 ↗
5. Macri, C., Dumont, C., Johnston, A. P. & Mintern, J. D. Targeting dendritic cells: a promising strategy to improve vaccine effectiveness. Clin. Transl. Immunol. 5, e66 (2016).10.1038/cti.2016.6 ↗
6. Alexander, J. et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®). Vaccine 22, 2362–2367 (2004).10.1016/j.vaccine.2003.11.061 ↗
7. Buonsanti, C. et al. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines. Sci. Rep. 6, 29063 (2016).10.1038/srep29063 ↗
8. Chen, P. et al. Dendritic cell targeted vaccines: recent progresses and challenges. Hum. Vaccines Immunother. 12, 612–622 (2015).10.1080/21645515.2015.1105415 ↗
9. Burgdorf, S., Kautz, A., Böhnert, V., Knolle, P. A. & Kurts, C. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 316, 612–616 (2007).10.1126/science.1137971 ↗
10. Sallusto, F., Cella, M., Danieli, C. & Lanzavecchia, A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182, 389–400 (1995).10.1084/jem.182.2.389 ↗
11. Pardee, A. D. et al. Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. J. Immunother. Cancer 3, 32 (2015).10.1186/s40425-015-0077-x ↗
12. Tsuji, T. et al. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J. Immunol. 186, 1218–1227 (2011).10.4049/jimmunol.1000808 ↗
13. Ekkens, M. J. et al. Th1 and Th2 cells help CD8 T-cell responses. Infect. Immun. 75, 2291–2296 (2007).10.1128/IAI.01328-06 ↗
14. Crotty, S. Follicular helper CD4 T cells (T FH). Annu. Rev. Immunol. 29, 621–663 (2011).10.1146/annurev-immunol-031210-101400 ↗
15. Declerck, P. J. Biologicals and biosimilars: a review of the science and its implications. Generics Biosimilars Initiat. J. 1, 13–16 (2012).10.5639/gabij.2012.0101.005 ↗
16. Pugholm, L. H., Petersen, L. R., Søndergaard, E. K. L., Varming, K. & Agger, R. Enhanced humoral responses induced by targeting of antigen to murine dendritic cells. Scand. J. Immunol. 82, 515–522 (2015).10.1111/sji.12387 ↗
17. Ninkovic, T. & Hanisch, F.-G. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J. Immunol. 179, 2380–2388 (2007).10.4049/jimmunol.179.4.2380 ↗
18. Jackson, D. C., Drummer, H. E., Urge, L., Otvos, L. Jr. & Brown, L. E. Glycosylation of a synthetic peptide representing a T-cell determinant of influenza virus hemagglutinin results in loss of recognition by CD4+ T-cell clones. Virology 199, 422–430 (1994).10.1006/viro.1994.1140 ↗
19. Liu, H. et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature 507, 519–522 (2014).10.1038/nature12978 ↗
20. Hartmann, D., Schneider, M. A., Lenz, B. F. & Talmadge, J. E. Toxicity of polyinosinic–polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethylcellulose in mice. Pathol. Immunopathol. Res. 6, 37–50 (1987).10.1159/000157040 ↗
21. Singh, S. K. et al. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur. J. Immunol. 41, 916–925 (2011).10.1002/eji.201040762 ↗
22. He, L.-Z., Weidlick, J., Sisson, C., Marsh, H. C. & Keler, T. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine. Cell. Mol. Immunol. 12, 719–728 (2014).10.1038/cmi.2014.100 ↗
23. Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway. Nat. Immunol. 3, 196–200 (2002).10.1038/ni758 ↗
24. Campbell, G. R. & Loret, E. P. What does the structure–function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine? Retrovirology 6, 50 (2009).10.1186/1742-4690-6-50 ↗
25. Webster, T. J. Safety of Nanoparticles (Springer, New York, 2008).
26. Colletier, J.-P., Chaize, B., Winterhalter, M. & Fournier, D. Protein encapsulation in liposomes: efficiency depends on interactions between protein and phospholipid bilayer. BMC Biotechnol. 2, 9 (2002).10.1186/1472-6750-2-9 ↗
27. Lee, M. H. et al. Liposomal texaphyrin theranostics for metastatic liver cancer. J. Am. Chem. Soc. 138, 16380–16387 (2016).10.1021/jacs.6b09713 ↗
28. Yang, J., Chen, H., Vlahov, I. R., Cheng, J.-X. & Low, P. S. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc. Natl Acad. Sci. USA 103, 13872–13877 (2006).10.1073/pnas.0601455103 ↗
29. Cox, M. A., Kahan, S. M. & Zajac, A. J. Anti-viral CD8 T cells and the cytokines that they love. Virology 435, 157–169 (2013).10.1016/j.virol.2012.09.012 ↗
30. Figdor, C. G., van Kooyk, Y. & Adema, G. J. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2, 77–84 (2002).10.1038/nri723 ↗
31. Iwasaki, A. & Medzhitov, R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5, 987–995 (2004).10.1038/ni1112 ↗
32. Rosales, C., Lowell, C. A., Schnoor, M. & Uribe-Querol, E. Neutrophils: their role in innate and adaptive immunity 2017. J. Immunol. Res. 2017, 9748345–2 (2017).10.1155/2017/9748345 ↗
33. Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H. & Allison, J. P. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356, 607–609 (1992).10.1038/356607a0 ↗
34. Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247–258 (2008).10.1038/nri2274 ↗
35. McHeyzer-Williams, L. J., Milpied, P. J., Okitsu, S. L. & McHeyzer-Williams, M. G. Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat. Immunol. 16, 296–305 (2015).10.1038/ni.3095 ↗
36. Lynn, G. M. et al. In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nat. Biotechnol. 33, 1201–1210 (2015).10.1038/nbt.3371 ↗
37. Hoffman, S. L., Vekemans, J., Richie, T. L. & Duffy, P. E. The march toward malaria vaccines. Am. J. Prev. Med. 49, S319–S333 (2015).10.1016/j.amepre.2015.09.011 ↗
38. Mosquirix; Common Name: Plasmodium falciparum and Hepatitis B Vaccine (Recombinant, Adjuvanted) 1–175 (CHMP, 2015).
39. Cohen, J., Nussenzweig, V., Vekemans, J. & Leach, A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccin. 6, 90–96 (2014).10.4161/hv.6.1.9677 ↗
40. Kester, K. E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337–346 (2009).10.1086/600120 ↗
41. Coccia, M. et al. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity. NPJ Vaccines 2, 95 (2017).10.1038/s41541-017-0027-3 ↗
42. Tewari, K. et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and αDEC-CSP in non human primates. Vaccine 28, 7256–7266 (2010).10.1016/j.vaccine.2010.08.098 ↗
43. Dockrell, D. H. Imiquimod and resiquimod as novel immunomodulators. J. Antimicrob. Chemother. 48, 751–755 (2001).10.1093/jac/48.6.751 ↗
44. Wiley, S. R. et al. Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3, 93ra69–93ra69 (2011).10.1126/scitranslmed.3002135 ↗
45. Plassmeyer, M. L. et al. Structure of the Plasmodium falciparum circumsporozoite protein, a leading malaria vaccine candidate. J. Biol. Chem. 284, 26951–26963 (2009).10.1074/jbc.M109.013706 ↗
46. Bongfen, S. E. et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27, 328–335 (2009).10.1016/j.vaccine.2008.09.097 ↗
47. Estey, T., Kang, J., Schwendeman, S. P. & Carpenter, J. F. BSA degradation under acidic conditions: a model for protein instability during release from PLGA delivery systems. J. Pharm. Sci. 95, 1626–1639 (2006).10.1002/jps.20625 ↗
48. Moad, G. RAFT polymerization to form stimuli-responsive polymers. Polym. Chem. 8, 177–219 (2017).10.1039/C6PY01849A ↗
49. Trinchieri, G. & Sher, A. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7, 179–190 (2007).10.1038/nri2038 ↗
50. Hirosue, S., Kourtis, I. C., van der Vlies, A. J., Hubbell, J. A. & Swartz, M. A. Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation. Vaccine 28, 7897–7906 (2010).10.1016/j.vaccine.2010.09.077 ↗
51. Silvie, O. et al. Hepatocyte CD81 is required for Plasmodium falciparum and Plasmodium yoelii sporozoite infectivity. Nat. Med. 9, 93–96 (2003).10.1038/nm808 ↗
52. Rénia, L. et al. A malaria heat-shock-like determinant expressed on the infected hepatocyte surface is the target of antibody-dependent cell-mediated cytotoxic mechanisms by nonparenchymal liver cells. Eur. J. Immunol. 20, 1445–1449 (1990).10.1002/eji.1830200706 ↗